We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
07 Dec 2020 - 11 Dec 2020
09 Dec 2020 - 18 Dec 2020
Virtual Venue

Flexible Contraceptive Ring Lasts for Whole Year

By HospiMedica International staff writers
Posted on 30 Aug 2018
Print article
Image: The Annovera reusable contraceptive ring (Photo courtesy of Hallie Easley / Population Council).
Image: The Annovera reusable contraceptive ring (Photo courtesy of Hallie Easley / Population Council).
A new self-administered hormonal contraceptive formed as a reusable, flexible silicone ring can prevent unwanted pregnancies for up to an entire year.

The Annovera contraceptive ring, developed by the global nonprofit organization Population Council (New York, NY, USA), is a soft, reusable flexible silicone ring (57 mm in diameter) loaded with segesterone acetate and ethinyl estradiol that can be inserted and removed by a woman herself. It is placed vaginally for 21 days and removed for the next seven. When not in use, it is washed and stored in a compact case, withstanding temperatures of up to 30°C, an important consideration for distribution and use in low-resource settings.

Results of the Phase 3 trial, which enrolled a total of 2,308 women across 27 study sites in the United States, Latin America, Europe, and Australia, showed that Annovera was 97.3% effective in preventing pregnancy when used as directed, with a similar risk profile to other combined hormonal contraceptives. Similarly, a boxed warning related to increased cardiovascular risk warns users who smoke. As yet, Annovera has not been adequately evaluated in women with a body mass index (BMI) greater than 29 kg/m2.

“Nearly half of all pregnancies in the United States are unintended, which can increase health risks for mom and baby,” said Julia Bunting, president of the Population Council. “For more than 60 years, the Population Council has been at the vanguard of global efforts to develop innovative family planning methods that meet women’s needs. Having a single contraceptive system that provides a full year of protection while under a woman’s control could be a game-changer for some women.”

Annovera is the sixth contraceptive technology that Population Council researchers have developed to address family planning needs around the world and brought to market through commercialization agreements, which are in use by an estimated 170 million women worldwide. Other contraceptives developed by the Population Council include the copper intrauterine device (IUD) ParaGard; the Mirena intrauterine system; the contraceptive implants Norplant and Jadelle; and Progering, a contraceptive vaginal ring for breastfeeding women.

Related Links:
Population Council

Print article
M.I ONE Co., Ltd


Copyright © 2000-2020 Globetech Media. All rights reserved.